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Abstract 
Gold nanoparticles (AuNPs) have been extensively studied within biomedicine due to their 
biocompatibility and low toxicity. In particular, AuNPs have been widely used to deliver 
photosensitiser agents for photodynamic therapy (PDT) of cancer. Here we review the state-
of-the-art for the functionalisation of the gold nanoparticle surface with both photosensitisers 
and targeting ligands for the active targeting of cancer cell surface receptors. From the initial 
use of the AuNPs as a simple carrier of the photosensitiser for PDT, the field has significantly 
advanced to include: The use of PEGylated modification to provide aqueous compatibility and 
stealth properties for in vivo use; Gold metal-surface enhanced singlet oxygen generation; 
Functionalisation of the AuNP surface with biological ligands to specifically target over-
expressed receptors on the surface of cancer cells and; The creation of nanorods and 
nanostars to enable combined PDT and photothermal therapies. These versatile AuNPs have 
significantly enhanced the efficacy of traditional photosensitisers for both in vitro and in vivo 
cancer therapy. From this review it is apparent that AuNPs have an important future in the 
treatment of cancer.  
 
Introduction 
The use of gold nanoparticles (AuNPs) in biomedicine has been widely studied due to their 
exceptional biocompatibility and low toxicity.1–3 In particular, AuNPs have been found to be 
ideal delivery agents for photosensitisers in photodynamic cancer therapy (PDT). The 
combination of photosensitisers with gold nanoparticles has several advantages, including the 
enhancement in the production of singlet oxygen and other reactive oxygen species, the 
possibility to disperse hydrophobic photosensitisers in aqueous solutions, and the ability to 
conjugate biological ligands to the photosensitiser-AuNPs for active targeted PDT.1 The use of 
gold nanoparticles for PDT is not limited to spherical nanoparticles. Other gold nanomaterials, 
including nanorods, nanostars and nanoclusters have also been reported as delivery agents 
for PDT.1 Interestingly, the use of other gold nanomaterials and shapes, especially gold 
nanorods, opens the possibility to combine PDT with other therapies such as photothermal 
cancer therapy (PTT).4  
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Photosensitisers can be conjugated to the AuNPs through different approaches based on self-
assembly. The use of these approaches, including covalent binding and electrostatic 
interactions, for the functionalisation of gold nanoparticles with photosensitisers will be 
described in this review. Furthermore, the use of active targeting for selective internalisation 
of the photosensitisers by specific cancer cells will also be reviewed. 
Self-assembly via a sulfur-gold bond 
The conjugation of photosensitisers to AuNPs via self-assembly was first reported by Russell 
and co-workers.5 In this work, a three-component system was synthesised based on a novel 
substituted zinc phthalocyanine with a C11 mercaptoalkyl tether (C11Pc) self-assembled to the 
surface of AuNPs (2-4 nm in diameter) in the presence of the phase transfer reagent 
tetraoctylammonium bromide (TOAB) (Figure 1a). The interaction between C11Pc and TOAB 
in the functionalised AuNPs (C11PcAuNPs) led to a considerable increase in singlet oxygen 
quantum yield, from φΔ=0.45 to φΔ=0.65, as compared to the free C11Pc in solution. 
Additionally, the presence of TOAB was beneficial for the systemic administration of the 
photosensitiser for PDT since it allowed the solubilisation of C11Pc in polar solvents.5 The 
three-component system was subsequently tested in vitro using HeLa cervical cancer cell line.6 
Following a 4-hour incubation, the C11Pc-functionalised AuNPs were successfully internalised 
by the HeLa cells, as shown in Figure 1b. Irradiation with a 690 nm diode laser for 20 minutes 
induced a photodynamic efficacy leading to 57 % cell death, a significant improvement from 
the 26 % cell death achieved when the free C11Pc was incubated with the cells.6 The PDT 
efficacy of these C11PcAuNPs were then examined in vivo, as reported by Camerin et al..7 C57 
mice subcutaneously implanted with amelanotic melanoma were treated with the 
C11PcAuNPs, dispersed in a Cremophor EL emulsion, via intravenous injection. The 
C11PcAuNPs largely accumulated within the tumour tissue, in significantly higher 
concentrations than the free C11Pc, and irradiation of the mice 3 h after injection successfully 
inhibited tumour growth leading to the animals staying tumour-free for ca. 6 days. The three-
component system therefore showed significant advantages with respect to the free 
photosensitiser. To enhance the PDT efficacy of the C11PcAuNPs, a larger concentration of 
the nanoparticle conjugates was required. However, this required a higher concentration of 
Cremophor emulsion which would be toxic in vivo.7 
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Figure 1. (a) Schematic representation of the synthesised C11PcAuNPs with the phase transfer 
reagent TOAB. (b) Combined confocal fluorescence and DIC images of HeLa cells following 
incubation with phthalocyanine-nanoparticle conjugates. The presence of the nanoparticle 
conjugates within the HeLa cells can be readily seen from the fluorescence emission (red) 
following excitation at 633 nm. Images reproduced from Wieder et al.6 with permission from the 
European Society for Photobiology, the European Photochemistry Association and the Royal 
Society of Chemistry.  
 
The retention of the photosensitiser in the serum, which is essential for PDT, can be enhanced 
by addition of polyethylene glycol (PEG).8 PEG is not only approved for human intravenous 
application but it also has a high resistance to protein adsorption, thus having the potential 
to avoid opsonisation by the reticuloendothelial system (RES).1 Russell and co-workers 
synthesised a novel nanoparticle system consisting of AuNPs functionalised with a mixed 
monolayer of PEG and C11Pc (C11Pc-PEG-AuNPs) (Figure 2a).9 The presence of PEG allowed 
for the solubilisation of the C11Pc-PEG-AuNPs in aqueous solutions. A further benefit of using 
PEG is the ability to conjugate the molecule to other biological ligands that can be used for 
targeted PDT, which will be discussed later. The water-dispersible C11Pc-PEG-AuNPs were 
used in vivo to treat C57/BL6 mice implanted with subcutaneous B78H1 amelanotic 
melanoma. The C11Pc-PEG-AuNPs were found in the serum in high quantities and were 
subsequently activated by light irradiation either 3 h or 24 h following injection. As shown in 
the Kaplan-Meier survival plot in Figure 2b, irradiation at 3 h induced the best results, leading 
to complete survival and no tumour-regrowth in 40 % of the treated mice. The tumour cell 
death was found to occur primarily due to vascular PDT damage. Furthermore, the authors 
a) b)
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found that, after initial accumulation of the C11Pc-PEG-AuNPs in the serum, the nanoparticles 
moved towards the liver and spleen ca. 1 week after injection, leading to excretion via the 
bile-gut pathway.9 
 
Figure 2. (a) Schematic representation of the synthesised C11Pc-PEG-AuNPs. (b) A Kaplan-Meier 
survival plot highlighting the responses of amelanotic melanoma following photodynamic therapy 
with the C11Pc-PEG-AuNPs. Black squares: control group (no conjugates injected), n = 15; red 
squares: mice treated 24 hours after injection of conjugates, n = 8; green squares: mice treated 3 
hours after injection of conjugates, n = 15. Image reproduced from Camerin et al.9 with permission 
from the European Society for Photobiology, the European Photochemistry Association and the 
Royal Society of Chemistry. 
 
As shown by Camerin et al.,9 the pegylated C11PcAuNPsproved to be ideal for in vivo PDT, 
leading to high photodynamic efficiency and tumour destruction. The zinc phthalocyanine 
photosensitiser chosen for these studies, C11Pc, was designed with a 11-atom carbon chain 
that connects the macrocycle of the phthalocyanine to the disulfide bond, which would allow 
for self-assembly to the surface of the AuNPs. The long carbon chain was chosen to avoid 
quenching of the fluorescence of the phthalocyanine due to interaction with the metallic core 
of the AuNPs. However, metal-enhanced fluorescence (MEF), by which the fluorescence of 
fluorophores placed near the surface of metallic nanoparticles can be enhanced, is gaining 
interest for PDT.10,11 MEF has been shown to be related to metal-enhanced singlet oxygen 
production (ME1O2), which would thus lead to an enhanced PDT effect.12 Both MEF and ME1O2 
are distance-dependent; fluorophores placed on or close to the metallic core of the 
nanoparticles can lead to fluorescence quenching but fluorophores placed between ca. 5-
30 nm from the metal surface can lead to MEF.12,13 Russell and co- workers compared the 
a) b)
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efficacy of the C11Pc photosensitiser to another substituted zinc phthalocyanine with a C3 
mercaptoalkyl tether (C3Pc).10 The core of the phthalocyanines was the same for C11Pc and 
C3Pc, the only difference between the two was the length of the carbon chain that connects 
the macrocycle to the AuNPs (Figure 3a). The authors synthesised AuNPs with a mixed 
monolayer of PEG and either C11Pc or C3Pc, yielding ca. 4 nm water-stable C11Pc-PEG-AuNPs 
and C3Pc-PEG-AuNPs. While the C11Pc photosensitiser had a higher fluorescence in solution, 
once conjugated with the AuNPs the C3Pc photosensitiser was found to be more fluorescent 
due to MEF. The increase in fluorescence for the C3Pc-PEG-AuNPs was correlated with an 
increased production of singlet oxygen (1O2). Both types of nanoparticles were tested in vitro 
with SK-BR-3 human breast adenocarcinoma cells. Internalisation of the nanoparticles was 
efficient for both but, upon irradiation at 633 nm, the C3Pc-PEG-AuNPs induced a far greater 
PDT effect (Figure 3c) than the C11Pc-PEG-AuNPs (Figure 3b), as a consequence of the 
enhanced production of 1O2. Cell viability was further confirmed using a CellTiter-Blue® cell 
viability assay, which showed that the PDT with the C11Pc-PEG-AuNPs (Figure 3d) induced 
negligible cell death while PDT with the C3Pc-PEG-AuNPs (Figure 3e) produced 85 % cell death 
with low C3Pc concentrations of 0.23 μM.10 This study highlights the importance of MEF for 
photodynamic therapy. Engineering the distance between the photosentisisers and the 
AuNPs can have a significant effect in PDT, leading to higher levels of cell death at lower 
concentrations of the drug. 
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Figure 3. (a) Structure of the AuNPs functionalised with either C3Pc (red) or C11Pc (blue). (b-c) 
Confocal fluorescence microscopy images of SK-BR-3 cells incubated with either (b) C11Pc-PEG-
AuNPs or (c) C3Pc-PEG-AuNPs after irradiation with a 633 nm laser for 6 min. Images are the 
composite of differential interference contrast (DIC), fluorescence from either C11Pc or C3Pc 
collected in the red channel (λex = 633 nm; above 650 nm) and fluorescence from propidium iodide 
collected in the pink channel (λex = 543 nm; 560-615 nm). Scale bars 5 μm. (d-e) CellTiter-Blue® 
cell viability assay for SK-BR-3 cells incubated with (d) C11Pc-PEG-AuNPs or (e) C3Pc-PEG-AuNPs. 
Cells were either irradiated with a 633 nm HeNe laser (d) orange, e) yellow) or non-irradiated (d) 
dark cyan, e) green). Staurosporine (+ve St) was used as a positive control for cytotoxicity via 
apoptosis. Error bars represent the SD (n = 3) within a 95 % confidence interval. Statistically 
significant difference between C11Pc-PEG-AuNPs and C3Pc-PEG-AuNPs is indicated by * at P < 
0.008 and ** at P < 0.0001, obtained using a two-tailed Student’s t-test, where P < 0.05 is 
considered statistically significant. Image adapted from García Calavia et al.10 with permission 
from the European Society for Photobiology, the European Photochemistry Association and the 
Royal Society of Chemistry. 
 
Conjugation via a thiolated linker 
The S-Au bond can also be used to conjugate linkers to which the photosensitisers are then 
attached. The use of such thiolated linkers can avoid the specific synthesis or modification of 
photosensitisers to introduce a thiol into their structure.  
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The use of thiolated PEG and other polymers 
The use of PEG as one such linker has been reported by several groups.14–16 Wang et al. 
reported the combination of PDT and plasmonic photothermal therapy (PTT) using 54 nm gold 
nanostars functionalised with a thiolated PEG, to which the photosensitiser chlorin e6 was 
attached via EDC (N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride)-NHS (N-
hydroxysuccinimide) chemistry.14 The use of a 671 nm laser induced the production of singlet 
oxygen by the chlorin e6 and simultaneously heated the functionalised nanostars, due to the 
PTT effect. The combination of the chlorin e6 with the nanomaterial not only induced a 75 % 
increase in the production of 1O2 as compared to the free chlorin e6, it also allowed for the 
double therapy effect via PDT and PTT. Internalisation of the functionalised nanostars by 
breast cancer and lung cancer cells was efficient, leading to a high PDT effect. The improved 
internalisation was correlated with the inhibition of tumour growth in vivo in breast tumour-
bearing mice. The combination of PDT and PTT for an enhanced tumour destruction was also 
performed using pH-responsive gold nanorods (AuNRs).17 Zhang et al. synthesised PEGylated 
AuNRs, to which chlorin e6 was conjugated via a hydrazone. The stability of such hydrazone 
bond is pH dependent and can be easily cleaved at acidic conditions. The chlorin e6 loses its 
fluorescence when it is conjugated to the AuNRs. However, upon cellular internalisation, the 
acidic environment inside the cells cleaves the hydrazone bond thus releasing the chlorin e6, 
which then regains its fluorescent properties. The chlorin e6 is only released when it reaches 
the acidic environment within the tumour tissue. At this point, PDT can be applied via chlorin 
e6 using a 664 nm wavelength, together with PTT via the AuNRs using a 808 nm wavelength. 
As reported in the previous study,14 the use of PDT/PTT enhanced the cytotoxicity and the 
inhibition of tumour growth than an individual therapy by itself.17 One of the reasons for the 
enhanced cell kill using the combination therapy is that ,during PDT, the oxygen in the tumour 
tissue is consumed by the treatment itself, leading to hypoxia and thus limiting the potential 
of the therapy. The use of PDT in conjunction with PTT can solve this problem as, following 
consumption of molecular oxygen in the tissue, PTT becomes the main therapy thus increasing 
the tumour killing effect.14  
Kolemen et al. reported another system with the potential to solve the hypoxia limitation of 
PDT.15 The authors used non-conventional chemical photosensitisers, endoperoxides of 
arenes, which lead to the production of 1O2 upon heating via controlled cycloreversion. 
Anthracene-based endoperoxides were conjugated to a thiolated PEG through an amide 
bond, which was then self-assembled onto the surface of gold nanorods. The irradiation of 
the functionalised AuNRs with 808 nm wavelength for 10 minutes was sufficient to induce ca. 
80 % cell death in HeLa cells. A further advantage of the use of endoperoxides as 
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photosensitisers is their irradiation with NIR light, which can penetrate deeper than 
commonly used red light into biological tissue, thus opening the possibility to treat deep-lying 
tumours.15 In a further attempt to increase light penetration into the tissue, Clement et al. 
attempted the use of X-ray irradiation for PDT.16 The photosensitiser verteporfirin was 
electrostatically attached to a thiolated PEG on the surface of 12 nm AuNPs. The use of X-ray 
irradiation did not lead to an increase in PDT efficiency in pancreatic cancer cells, as was seen 
when the cells were irradiated with a 690 nm laser. The authors claimed that the combination 
of X-ray and 690 nm irradiation could hold the potential to actively treat deep-lying tumours 
but further studies are required to confirm these claims.16 
Thiolated polymers other than PEG have also been studied for the conjugation of 
photosensitisers to gold nanomaterials.18,19 Gamaleia et al. studied the conjugation of 
haematoporphyrin to 15 and 45 nm AuNPs via polyvinylpyrrolidone.18 Leukemia cells were 
treated with the haematoporphyrin-functionalised AuNPs and subjected to 635 nm PDT. Both 
conjugates were shown to increase the PDT effect as compared to the free photosensitiser, 
with the 45 nm sized AuNPs performing best.18 As previously mentioned, PDT can be 
combined with other therapies including photothermal therapy (PTT). Hollow gold 
nanospheres (HAuNS) have been functionalised with branched polyethylenimine (PEI), to 
which the photosensitiser indocyanine green (ICG) was covalently attached.19 The conjugation 
of ICG on the HAuNS allowed for their stability in aqueous solutions and, more importantly, it 
improved the absorption of the system within the NIR region. The increased NIR absorption 
is advantageous for an enhanced PTT effect. The as-prepared ICG-PEI-HAuNS were tested in 
vitro in 2D and 3D human ovarian carcinoma tumour models, as well as in vivo in mice bearing 
either colon carcinoma CT26 cells or metastatic melanoma B16 cells. All studies suggested 
that the combination of PDT with PTT showed significantly better results than the use of either 
single therapy. The in vitro studies in 2D models showed a moderate improvement of PTT/PDT 
efficacy using the ICG-PEI-HAuNS as compared to the free ICG. Additionally, the 3D models 
showed significant tumour reduction, even though the percentage of cell kill was not as high 
as in 2D models. The use of the conjugates in vivo showed selective accumulation within the 
tumour tissue and 100 % survival of the treated mice until day 40, a considerable 
improvement to the mice treated with only ICG or only HAuNS, which survived until days 28 
and 32, respectively. The ICG-PEI-HAuNS were further found to inhibit tumour metastasis in 
vivo by destroying both the cancer cells and the surrounding blood vessels.19 
The use of mercapto moieties 
The use of linkers based on mercapto moieties to conjugate AuNPs to photosensitisers has 
been reported in the literature.20–22 The linker 6-mercapto-1-hexanol was self-assembled on 
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the surface of 7 nm AuNPs by Eshghi et al..20 Protoporphyrin IX was then conjugated to the 
linker via N,N’-dicyclohexylcarbodiimide (DCC)-promoted coupling. The AuNPs system 
allowed the internalisation of the hydrophobic porphyrin photosensitiser by HeLa cervical 
cancer cells and the PDT effect was confirmed with red light irradiation at 630 nm.20 Other 
research groups have chosen mercaptopropionic acid as the linker for the conjugation of 
photosensitisers to the AuNP core.21,22 A meso-tetrahydroxyphenylchlorin (mTHPC) was 
attached to mercaptopropionic acid self-assembled on 12 nm AuNPs through esterification 
between the hydroxyl groups of mTHPC and the carboxyl group of the mercaptopropionic 
acid.21 The authors confirmed the PDT potential of the water-soluble mTHPC-functionalised 
AuNPs in vitro using neuroblastoma cells. The combination of the mTHPC with the AuNPs was 
shown to induce less dark toxicity to the cells than the free mTHPC, thus allowing for the 
application of higher drug doses for enhanced PDT without leading to any side-toxicity in the 
absence of light. The major disadvantage of this system was the long irradiation times needed, 
of up to 1 h, to reach high levels of cell death, which could prove problematic for in vivo clinical 
applications.21 In another system, AuNPs were functionalised with porphyrin-brucine 
photosensitiser conjugates via 3-mercaptopropionic acid.22 This system had a different 
outcome to what was described previously. In vitro studies in basaloid squamous carcinoma 
cells showed a lower efficiency of the functionalised AuNPs as compared to the free 
photosensitisers, which was attributed to the aggregation of the AuNPs in aqueous media. On 
the contrary, in vivo studies showed efficient PDT leading to tumour reduction in the mice 
treated with the functionalised AuNPs. The authors suggested that the good effect in vivo was 
due to the interactions of the functionalised AuNPs with plasma proteins, such as human 
serum albumin (HSA), which led to the generation of supramolecular complexes, thought to 
enhance PDT.22 
Other thiolated linkers 
The conjugation of photosensitisers via alternative thiolated linkers has been widely explored. 
The selected linkers include multidentate passivant ligands,23 cysteine,24 thiourea,25 
glutathione,26 lipoic acid,27 and imidazole containing linkers.28 
The use of multidentate passivant ligands for the conjugation of a porphyrin to AuNPs was 
explored by Ohyama et al..23 It has been reported that such passivant ligands have the ability 
to stabilise AuNPs as a substitute to the commonly used citrate or TOAB stabilisers. The 
authors synthesised a porphyrin-based tetradentate passivant, consisting of four sulfur atoms 
which can be self-assembled onto the surface of the AuNPs. The presence of the four sulfur-
Au bonds allows for the creation of a horizontal porphyrin monolayer around the AuNPs. This 
type of surface-engineered photosensitiser coated AuNPs are promising PDT agents but their 
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in vitro or in vivo efficacy has yet to be evaluated.23 More commonly used linkers include 
cysteine, thiourea and glutathione. Cysteine self-assembled onto the surface of AuNPs can be 
covalently conjugated to photosensitisers, such as protoporphyrin IX (PpIX), inducing up to 
59 % cell death for spermatogonial cells upon irradiation at 633 nm.24 Additionally, the use of 
a cysteine linker opens the possibility to conjugate the cysteine to other molecules, such as 
targeting ligands for selective PDT, which will be reviewed later in this article. Vieira et al. used 
thiourea as the linker between 18 nm AuNPs and chlorin e6, using EDC-NHS coupling for the 
interaction between the linker and the photosensitiser.25 The system was shown to be 
efficient following 4 h incubation with breast carcinoma cells and PDT at 660 nm, leading to 
higher levels of cell death than the free chlorin e6 in solution.25 Hari et al. developed water-
stable 14 nm chitosan reduced AuNPs functionalised with glutathione, which was 
electrostatically bound to the photosensitiser acridine orange.26 The high loading of 
photosensitiser yielded highly fluorescent AuNPs conjugates with an enhanced PDT effect in 
vitro. The irradiation at 492 nm induced not only the production of singlet oxygen via 
activation of the acridine orange, but it was also reported that an increase in temperature was 
induced with the AuNPs acting as the photothermal agents. Therefore, it was suggested that 
this nanoplatform can be used for a dual PDT/PTT therapy.26 
The Pérez-García group has developed several nanoplatforms with non-conventional linkers 
for the conjugation of photosensitisers for PDT.27,28 The group studied the photodynamic 
effect of three gold-based nanoplatforms, differing in size and shape, conjugated to porphyrin 
photosensitisers via a lipoic acid linker.27 The nanoplatforms of choice were AuNPs, cobalt-
nickel nanorods covered with a gold shell (NRs) and hexahedral Janus microparticles (μP) with 
two surfaces, gold and polysilicon. The geometric areas of each platform were, respectively, 
3.1×10-4 μm2, 1.3 μm2 and 9 μm2. The lipoic acid linker was self-assembled onto the gold 
surface of the nanoplatforms, to which porphyrin photosensitisers were attached through 
amide bonds. To induce water solubility, the AuNPs and NRs were additionally functionalised 
with 11-mercaptoundecyl)hexa(ethylene glycol) (MHEG), a PEG derivative. The μP were 
functionalised with 6-{2-[2-(2-methoxyethoxy) ethoxy]ethoxy}hexyl) trimethoxysilane 
(MTMS) on the polysilicon surface, which allowed for the dispersion of the μP in aqueous 
solutions. The size and shape of the nanoplatforms was found to play a key role in the PDT 
efficacy in vitro. The NRs were subjected to intrinsic toxicity and their magnetism induced 
aggregation, thus lowering the efficacy of PDT. The μP were internalised in smaller amounts 
than the other nanoplatforms, due to their large size. However, the large size was 
advantageous as it included more porphyrins per particle than the smaller sized-AuNPs, 
translating into a good PDT effect. Nevertheless, it was the AuNPs that induced the best 
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photocytotoxicity in vitro, thus concluding that the smaller size was beneficial for cell 
internalisation and also PDT.27 
In a more recent study, Pérez-García and co-workers conjugated zinc porphyrins to the surface 
of AuNPs via zinc-imidazole axial coordination.28 The surface of 7 nm AuNPs was engineered 
to contain a thiolated PEG ligand, to induce water solubility, and a thiolated 1-(11-
mercaptoundecyl)imidazole (Im-C11-SH). The zinc porphyrin Zn(II)meso-tetrakis(4-
carboxyphenyl)porphyrin was conjugated to the AuNPs via a Zn-imidazole coordinative bond. 
The conjugation of the porphyrin in this way allows it to adopt a horizontal orientation relative 
to the surface of the AuNPs, which can be advantageous to avoid the formation of aggregates 
since it reduces the maximum number of porphyrins that can be incorporated into the system. 
The formation of the porphyrin-imidazole functionalised AuNPs highly increased the 
production of reactive oxygen species as compared to the free porphyrin in solution. 
Additionally, in vitro PDT studies with 30 min irradiation using wavelengths between 400-
500 nm induced up to 80 % cell death with a concentration of 1.75 μM of porphyrin within 
the nanosystem. The use of imidazole coordination provides a simple and stable coordinate 
bond, in contrast to the commonly used covalent bonds, and holds great potential for future 
in vivo PDT studies since numerous photosensitisers can be readily coordinated to the AuNPs 
without the need for specialist synthesis of anchor moieties.28 
The use of the N-Au bond 
Conjugation between AuNPs and photosensitisers via N-Au bonds has been particularly 
studied by the Burda group.29–31 The N-Au is a weak bond,  with a bond energy of 6 kcal/mol, 
in comparison with the S-Au bond, which has a bond energy of 47 kcal/mol.29 Therefore, the 
functionalisation of AuNPs with photosensitisers using the N-Au bond requires other 
stabilising ligands, such as PEG derivatives. Burda and co-workers developed 5 nm AuNPs 
functionalised with a thiolated PEG and attached to the terminal amine on a silicon 
phthalocyanine 4 (Pc4) axial ligand through a N-Au bond. The presence of PEG provides steric 
repulsion between AuNPs and also enables the stabilisation of the Pc4 on the AuNPs via van 
der Waals interactions. Therefore, the Pc4 is entrapped in what the authors define as a ‘cage-
type structure’, allowing the solubilisation of the hydrophobic drug in aqueous solutions. A 
further advantage of the use of PEG is the low protein adsorption and increased circulation 
time in the serum, which is essential for PDT.1,30 Given the van der Waals interactions between 
PEG and Pc4 on the surface of the AuNPs, the photosensitiser is forced to adopt a horizontal 
orientation relative to the Au core. While this orientation can potentially enable up to 100 Pc4 
molecules per AuNP, only 30 Pc4 molecules were conjugated.29,30 The mechanism of action of 
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the synthesised nanosystem consists on the selective delivery of the drug to the tumour tissue 
via the enhanced permeability and retention effect (EPR). Upon delivery towards the tumour 
tissue, Pc4 is released from the AuNPs due to the attraction of the hydrophobic Pc4 to the 
lipid bilayers of the cell membrane and the weak binding between Pc4 and the AuNPs. The 
release of the drug is beneficial since, upon conjugation with the AuNPs the fluorescence of 
Pc4 is slightly quenched. The release of Pc4 allows for the recovery of the fluorescence. While 
Pc4 is internalised by the cancer cells, the AuNPs remain in the extracellular space. In vitro 
studies showed that, upon internalisation, Pc4 moves towards the mitochondria leading to 
remarkable PDT effects.30 
The Pc4-PEG-AuNPs were evaluated in vivo to investigate both the PDT effect in animal tissues 
and the pharmacokinetics and excretion from the body.29,31 The most important advantage of 
the use of Pc4-PEG-AuNPs versus free Pc4 is the length of time it takes the drug to reach the 
tumour tissue, which can be reduced from ca. 48 h to less than 2 h when conjugated to the 
AuNPs.29 The fate of the Pc4 and the PEGylated AuNPs within the body was studied over a 7-
day period. Even though the Pc4 and the AuNPs followed different routes and accumulated in 
different organs, both components were found to be excreted via the renal and hepatobiliary 
systems.29,31 The Burda group has broadened these studies by introducing biological ligands 
for targeted PDT, which will be discussed later.  
Electrostatic interaction 
Photosensitisers can be conjugated to charged, either positively or negatively, gold 
nanoparticles. Several research groups have shown the advantages of using such conjugation 
for PDT.11,32–36 The effect of the size of AuNPs electrostatically bound to the photosensitiser 
PpIX was studied with AuNPs of diameters 19, 66 and 106 nm.32 Cationic AuNPs were 
synthesised with branched polyethyleneimine (BPEI) reduction, which were functionalised 
with the negatively charged PpIX. The authors found that, in solution, the larger sized AuNPs 
correlated with an increased production of singlet oxygen. Furthermore, in vitro studies in 
MDA-MB-231 human breast adenocarcinoma cells showed that the larger AuNPs (106 nm) 
were not as easily internalised by the cells as the smaller AuNPs (19 and 66 nm). As a result, 
the 66 nm AuNPs induced the highest intracellular production of ROS. While the free PpIX in 
solution was only able to kill 22.6 % of the cells treated with 532 nm PDT, the attachment of 
PpIX on the surface of either of the AuNPs (16, 66 or 106 nm) induced over 50 % cell death 
post-PDT. The higher intracellular uptake and higher production of singlet oxygen by the 
66 nm AuNPs was associated with the highest cell death in vitro.32  
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The compound 5-aminolevulinic acid (5ALA) is commonly used in PDT since it is a natural 
precursor of the photosensitiser PpIX produced during the biosynthesis of haem.1 The 
electrostatic conjugation of 5ALA to AuNPs has been reported with promising results for 
PDT.33,34 Xu et al. synthesised 24 nm AuNPs functionalised with BPEI and 5ALA in a similar 
manner as reported above for the conjugation of PpIX to AuNPs.33 The authors tested their 
conjugates in vitro using K562 chronic myelogenous leukaemia cells and found that the AuNPs 
enhanced the singlet oxygen production and intracellular uptake of 5ALA. Additionally, 
enhanced selectivity towards tumour cells, due to the positively charged AuNPs, which are 
attracted to cancer cells given their higher negative-zeta potential than healthy cells, was 
reported. An incubation time of 4-6 hours combined with green light irradiation was shown 
to be ideal for PDT, given the low intrinsic toxicity of the green light itself.33 Similar results 
were obtained by Mohammadi et al. in Mel-Rm metastatic melanoma cells.34 The combination 
of 5ALA with AuNPs was found to be advantageous since lower concentrations of the 5ALA on 
AuNPs lead to the same phototoxicity than higher concentrations of unconjugated 5ALA, thus 
limiting the potential damage of high concentrations of 5ALA on healthy cells.34 
The use of MEF, previously discussed for AuNPs functionalised with thiolated 
photosensitisers, has also been studied for electrostatically bound drugs. Huang et al. 
conjugated CTAB stabilised-AuNRs with chlorin e6 through electrostatic interactions.11 The 
authors proved that the close distance between AuNRs and chlorin e6 enhanced the 
fluorescence of the photosensitiser. The increase in fluorescence correlated with an improved 
production of singlet oxygen and thus it translated into three times more efficient PDT in vitro 
as compared to free chlorin e6.11  
Electrostatic conjugation of photosensitisers to AuNRs has also been reported for combined 
PDT/PTT therapies.35,36 Jang et al. synthesised cetyltrimethylammonium bromide (CTAB) 
coated AuNRs, further functionalised with a thiolated PEG and a thiolated positively charged 
peptide, to which the negatively charged photosenstiser Al(III) phthalocyanine chloride 
tetrasulfonic acid (AlPcS4) was electrostatically attached.35 The fluorescence of AlPcS4 was 
quenched upon conjugation to the AuNRs, but it could be recovered when the drug was 
released. Up to 80 % of the drug could be released in physiological conditions after 24 h. The 
combination of AlPcS4 with AuNRs allowed for effective delivery into cancer cells both in vitro 
and in vivo, up to four times higher than for the free photosensitiser. Following internalisation 
and release of the drug, an enhanced cell death was seen for the AlPcS4-AuNRs (78 %) as 
compared to the free AlPcS4 (36 %). More importantly, the combination of PDT at 670 nm and 
PTT at 810 nm efficiently inhibited 95 % of the tumour growth in vivo, a considerable 
improvement of the 79 % enhancement when PDT was performed as a single therapy. Despite 
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the promising results seen, the authors speculated that further optimisation of the PTT 
conditions could lead to better results.35 The main disadvantage with this method was the 
need to use two different irradiation wavelengths for PDT and PTT. Bhana et al. developed a 
system where PDT and PTT could be achieved with a single wavelength, 808 nm.36 The authors 
electrostatically conjugated CTAB-pegylated AuNRs to the photosensitiser silicon 2,3-
naphthalocyanine dihydroxide (SiNC), which were stabilised with alkylthiols of different 
lengths. The alkylthiols used were 6-mercaptohexanoic acid, 11-mercaptoundecanoic acid 
and 16-mercaptohexadecanoic acid, varying in the length of the carbon atom chain (5, 10 and 
15 atoms, respectively). A concentration of 0.5 nM of SiNC induced complete cell destruction 
regardless of the length of the alkylthiol used. However, at low concentrations of the drug, 
the PDT/PTT efficiency was enhanced with the longest akylthiol.36  
The group of Pérez-García have investigated the use of amphiphilic gemini-type pyridinium 
salts for conjugation of porphyrins to AuNPs.37 These types of salts have been described as 
stabiliser agents for AuNPs.38,39 However, this study is the first report of the use of a bis-
pyridinium salt (1∙2Br) not only to stabilise the AuNPs but also to anchor the photosensitiser 
via electrostatic interactions. The authors functionalised 7-10 nm AuNPs with a mixture of 
1∙2Br and PEG, to provide aqueous solubility, and an anionic porphyrin as the photosensitiser. 
The nanosystem was shown to hold great potential for PDT since SK-BR-3 human breast 
adenocarcinoma cells were more highly damaged than non-tumorigenic mammary epithelial 
MCF-10A cells.37 
Conjugation to silica coated gold nanomaterials 
The conjugation of photosensitisers can be achieved through encapsulation in a silica shell 
surrounding a gold nanocore, as reported by various research groups.40,41 Silica coated gold 
nanoplatforms haven been used not only for PDT and combination therapies, but also to 
include surface-enhanced Raman scattering (SERS) detection and imaging of tumour tissue.40 
Gold nanostars have been coated with 3,3’-diethylthiatricarbocyanine iodide (DTCC) as the 
SERS tag, and then covered with a mesoporous silica shell into which the photosensitiser 
methylene blue was encapsulated. The use of gold nanostars is not arbitrary since they induce 
better SERS enhancement than conventionally used spherical AuNPs. SERS-enhanced imaging 
was performed using a 785 nm wavelength, while the PDT treatment was performed by 
irradiating the methylene blue in the nanosystem using 633 nm light. The combination of 
DTCC and methylene blue in the same system was advantageous for the development of 
theranostics, by which diagnosis (via SERS imaging) and therapy (via singlet oxygen generation 
during PDT) can be simultaneously performed.40 Seo et al. developed a similar system, based 
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on pegylated gold nanorods (AuNRs) coated with a silica shell in which methylene blue was 
embedded via physical adsorption.41 The substitution of gold nanostars by AuNRs can be 
advantageous since it opens the possibility to add the additional therapy of PTT. Irradiation 
with a single NIR wavelength, 780 nm for 50 minutes, was sufficient to induce combined PDT 
and PTT damage, together with SERS imaging for theranostic applications. The improvement 
in cell death through the combination of PDT and PTT was confirmed by the levels of cell death 
for bare AuNRs, 69 %, as compared to the methylene blue-silica-coated AuNRs, 89 %.41 
Therefore, this system is a promising alternative for theranostics in cancer treatment. The 
covalent conjugation of silica coated gold nanoclusters with chlorin e6 via EDC/NHS coupling 
has been reported for fluorescence imaging-guided PDT.42 Covalent conjugation of a 
photosensitiser to silica coated gold nanoclusters was found to have several advantages 
including a high loading of the drug (14.6 wt%), no leakage of the photosensitiser during 
circulation in the serum and enhanced PDT damage at 671 nm leading to efficient inhibition 
of tumour growth in vivo.42   
In a somewhat different system, silica nanoparticles containing a gold core have been 
reported for PDT/PTT combination therapy.43 Ricciardi et al. have synthesised ca. 40 nm silica 
nanoparticles in which a cyclometalated iridium (III) complex (Ir1) was embedded. 
Additionally, the silica nanoparticles contained a gold core (Ir1-AuSiO2). The conjugation of Ir1 
to the AuSiO2 nanoparticles produced a decrease in the singlet oxygen quantum yield from 
0.97 for the free Ir1 to 0.22 for the Ir1-AuSiO2. However, U87MG glioblastoma cells internalised 
the conjugate (Ir-AuSiO2) more efficiently than the free Ir1, thus cell death was enhanced upon 
conjugation of Ir1 to the AuSiO2. Light irradiation for combined PDT/PTT was performed via 
700 nm two photon excitation, able to reach deep-lying tumours. More importantly, the 
introduction of the gold core in the silica nanoparticles was found to be key for an enhanced 
tumour destruction at lower concentrations of the drug.43 The nanoplatform presented in this 
study holds potential for the development of a highly efficient, deep-penetration cancer 
therapy. 
Alternative conjugation methods for gold-mediated PDT 
The development of other conjugation methods and platforms based on gold by which 
efficient PDT can be achieved have also been reported in the literature.44–49 Hu et al. used a 
LayerbyLayer (LbL) method to assemble the photosensitiser Al(III) phthalocyanine chloride 
tetrasulfonic acid (AlPcS4) onto gold nanorings.44 In this case, LbL assembly consists of 
successive deposition of layers of the photosensitiser around the gold. The authors 
synthesised gold nanorings covered with a layer of thiolated PEG. A layer of a cationic 
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polymer, poly(allylamine hydrochloride) (PAH), was then added to allow for the electrostatic 
interaction with the photosensitiser, a layer of which was added on top of the PAH. A second 
layer of PAH followed by AlPcS4 was attached, creating a system with two full layers of 
photosensitiser. The conjugation of the photosensitiser with gold induced a quenching effect, 
as seen in many systems reported in this review. However, upon internalisation by the cells, 
the AlPcS4 drug was efficiently released, regaining its fluorescence and ability to produce ROS. 
The addition of the second AlPcS4 layer was key for an enhancement in PDT relative to the 
free photosensitiser, reaching levels of up to 85 % cell death following 6 h incubation with 
MDA-MB-231 breast cancer cells and NIR irradiation for ROS generation.44 
Other studies have shown alternative nanosystems. Cui et al. developed a gold cluster 
nanoassembly.45 The conjugation of BSA and cysteine-stabilised gold nanoclusters with 
glutathione resulted in the cleavage of the BSA intramolecular disulfide bonds and the 
formation of new intermolecular disulfide bonds, thus creating a nanoassembly of many gold 
nanoclusters coming together. The nanoassembly itself was also used as the photosensitiser. 
The use of the nanoassembly showed an improvement in PDT efficacy as compared to the 
single gold nanoclusters. However, only moderate levels of cell death were achieved, 
considerably less than other systems described in this review.45 In a recent report, Yan et al. 
have developed a system based on AuNRs and chlorin e6.46 The surface of 70×17 nm AuNRs 
was modified with poly(styrene sulfonate) (PSS) and the chlorin e6 was conjugated to 
branched PEI, both polymers used for an increased stability in aqueous solutions. The PSS-
AuNRs and PEI-Chlorin e6 are not directly attached to one another, but they are both 
assembled onto a template, which the authors refer to as a ‘plaster’. The presence of the 
AuNRs and chlorin e6 on such a plaster allows for combined PTT (808 nm) and PDT (660 nm), 
leading to complete tumour destruction following 16 days after treatment in vivo. Such a 
plaster system is advantageous since it is non-invasive and can be used in numerous occasions 
to treat tumours. However, its application is limited to superficial tumour lesions due to the 
nature of the plaster application.46 
Other nanoparticle systems all supported by gold include liposomes loaded with AuNPs,47 
carboxymethyl dextran nanoparticles stabilised with gold,48 and the use of a thin shell of gold 
comprised of a gold sulfide (Au2S) dielectric core.49 Liposomes loaded with 3-5 nm AuNPs and 
the photosensitiser Rose Bengal were particularly efficient for PDT combined with 
chemotherapy, when the chemotherapeutic drug doxorubicin was included within the 
system.47 The use of gold to stabilise carboxymethyl dextran nanoparticles loaded with the 
photosensitiser chlorin e6 was advantageous since it increased the tumour selectivity and 
thus the PDT effect in vivo.48 Finally, the physical adsorption of gold-sulfide gold (Au-Au2S) 
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with the photosensitiser ICG was found to be a promising alternative for NIR-PDT/PTT given 
the non-toxic nature of Au-Au2S and their easy internalisation by tumorigenic cells.49 
AuNPs should not only be considered as nanocarriers for the delivery of photosensitisers but 
can be used as the phototoxic agents themselves. El-Hussein et al.50 have shown the uptake 
and phototoxicity of 50 nm diameter AuNPs on MCF-7 and A549 cancer cells upon laser 
irradiation. The cytotoxicity observed was similar to that of a laser activated phthalocyanine 
used as control, although the cytotoxicity was not as efficient as that induced by non-
functionalised silver nanoparticles, which can also be used as phototoxic agents themselves.50 
Actively targeted PDT 
The nanoparticle systems described above typically rely on the enhanced permeability and 
retention (EPR) effect for selective accumulation within the tumour tissue, known as passive 
targeting. The EPR effect is related to the creation of abnormal, leaky and loosely-connected 
blood vessels in the tumour tissue via angiogenesis and the lack of lymphatic drainage in the 
tumour interstitial fluid, responsible for the nanoparticles permeating and being retained.51 
The use of gold nanoparticles provides the opportunity to additionally use biological ligands 
in order to further increase the selectivity towards tumours, i.e., active targeting. Targeting 
ligands are responsible for the selective interaction between the nanoparticles and specific 
receptors overexpressed on the surface of tumour cells, but not healthy cells, thus increasing 
internalisation.52 Figure 4a shows the receptors that have been targeted, in different cancer 
cells, using gold nanoparticles. The most commonly targeted receptors include the epidermal 
growth factor receptors 1 (EGFR) and 2 (HER2),  αvβ integrins, the transferrin receptor, 
nucleolin, the folate receptor, cluster determinants 44 (CD44), and the aberrant glycosylation 
on cancer cells, including overexpressed carbohydrates and endogenous lectins.1 Gold 
nanoparticles can be functionalised with ligands that selectively target these receptors. The 
reported targeting ligands conjugated to gold nanoparticles for PDT that will be reviewed in 
this paper include antibodies, carbohydrates and lectins, peptides, aptamers, folic acid and 
hyaluronic acid (Figure 4b). 
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Figure 4. (a) Schematic representation of a cell membrane, showing some of the overexpressed 
cancer cell receptors that can be used for selective targeting. It should be noted that these 
receptors are not all present in all cancer cell types. (b) Schematic representation of a gold 
nanoparticle functionalised with the ligands that are commonly used to target overexpressed 
receptors on cancer cells. It should be noted that these ligands are not all present in the same 
nanoparticle. Image (a) was adapted from García Calavia and Russell1 with permission from the 
European Society for Photobiology, the European Photochemistry Association and the Royal 
Society of Chemistry. 
 
Antibodies 
The most commonly reported biological ligand used for targeting PDT is antibodies. 
Antibodies have a strong binding affinity towards their antigen of interest, with dissociation 
constants (kd) within the 10-8-10-12 M range.53 Several studies have reported the conjugation 
of antibodies to PEGylated AuNPs using EDC-NHS coupling to the terminal carboxylic acid of 
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the PEG chain.54–56 As previously described, Russell and co-workers synthesised stable C11Pc-
PEG-AuNPs with good photodynamic toxicity in vitro and in vivo. The group further increased 
the selectivity of the C11Pc-PEG-AuNPs to breast cancer cells using anti-HER2 antibodies. The 
HER2 receptor is found overexpressed in ca. 10-34 % of aggressive breast cancers, thus 
becoming an important target for selective PDT.54 Stuchinskaya et al. prepared the four-
component anti-HER2 antibody-C11Pc-PEG-AuNPs (Figure 5a) and showed that the addition 
of the antibody did not alter the ability of the nanoparticles to produce singlet oxygen.55 The 
authors confirmed the importance of the antibody to achieve high selectivity by comparing 
three mammary cell lines; HER2 positive SK-BR-3 human breast adenocarcinoma cells, HER2 
negative MDA-MB-231 human breast adenocarcinoma cells and non-tumorigenic MCF-10A 
human mammary epithelial cells. In vitro PDT studies using an irradiation wavelength of 
633 nm showed apoptotic cell death levels of 60 % for SK-BR-3 cells, 25 % for MDA-MB-231 
cells and 7 % for MCF-10A cells, indicating that the selective interaction between anti-HER2 
antibody and the HER2 receptor on the surface of SK-BR-3 cells leads to an increased 
internalisation and thus enhanced PDT efficacy.55 The reported anti-HER2 antibody-C11Pc-
PEG-AuNPs were shown to be internalised efficiently, initially locating around the cell 
membrane (Figure 5b) and moving towards the acidic organelles, i.e., the lysosomes, over 
time (Figure 5c), leading to efficient cell death (Figure 5d). In a more recent study, Penon et 
al. synthesised water-stable AuNPs functionalised with a thiolated porphyrin derivative as the 
photosensitiser, and PEG as the stabilising agent to induce water solubility.56 Anti-HER2 
antibody was further conjugated to the system through the PEG and SK-BR-3 cells were 
targeted in vitro. Irradiation of the cells between 530-585 nm using a fluorescence microscope 
allowed the visualisation of cell death using the dead cell marker propidium iodide.56  
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Figure 5. (a) Schematic representation of the anti-HER2 antibody functionalised C11Pc-PEG-
AuNPs. (b-d) Confocal fluorescence microscopy images of SK-BR-3 cells incubated with anti-HER2 
antibody functionalised C11Pc-PEG-AuNPs either before irradiation (b-c), right after incubation 
(b) or 19 h after incubation (c), or after irradiation (d) with a 633 nm laser for 6 min. Images are 
the composite of differential interference contrast (DIC), fluorescence from C11Pc collected in the 
red channel (λex = 633 nm; above 650 nm) and fluorescence from propidium iodide collected in 
the pink channel (λex = 543 nm; 560-615 nm). Scale bars 5 μm.  
 
The human epidermal growth factor receptor 1, also known as EGFR, has also been widely 
targeted via antibodies.57–60 Kuo and co-workers synthesised CTAB-stabilised AuNRs (35 nm × 
9.3 nm in size) conjugated to poly(styrene-altmaleic acid) (PSMA), to which the 
photosensitiser ICG was electrostatically attached.57 Additionally, the negatively charged ICG 
was functionalised with anti-EGFR antibodies electrostatically, due to the presence of 
positively charged antibody fragments. The combination of the AuNRs with ICG was optimal 
for the combined action of PDT and PTT following NIR irradiation at 808 nm. The antibody-
ICG-functionalised AuNRs were found to induce no damage to A549 lung carcinoma cells in 
b) c) d)
a)
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the absence of light but killed up to 98 % cells upon irradiation.57 The authors further 
broadened their study by investigating the use of AuNPs instead of AuNRs. The 
functionalisation of AuNPs with branched PEI, electrostatically conjugated to ICG and anti-
EGFR antibodies, was also found to be useful for combined PDT/PTT. However, the size of the 
AuNPs core was key for efficacy of the treatment, with larger AuNPs inducing a better 
photochemical effect. The sizes of AuNPs studied were 13 nm, 50 nm and 100 nm, which 
induced, respectively, 66 %, 80 % and 92 % cell death following treatment.58  
The Kiang group has also reported the use of anti-EGFR antibodies for targeted PDT.59,60 This 
research group focuses on the synthesis of gold nanorings functionalised with a thiolated PEG, 
a sulfonated aluminium phthalocyanine (AlPcS) and a 16-mercaptohexadecanoic acid, acting 
as the linker to anti-EGFR antibodies. The group was able to perform PDT in combination with 
PTT using an irradiation wavelength of 1,064 nm for PTT but also as a two-photon excitation 
of the AlPcS photosensitiser for PDT, in conjunction with the more conventionally used 
660 nm wavelength for the irradiation of phthalocyanines for PDT.59,60 
Lectins and carbohydrates 
Carbohydrates and lectins, carbohydrate-binding proteins, are both expressed on the surface 
of all healthy human cells and play important roles in the organism including, but not limited 
to, cell growth, cell differentiation and adhesion, and cell signalling.61 The expression of 
carbohydrates and lectins on the surface of cancer cells can change, leading to over- or under-
expression of specific receptors. This aberrant glycosylation in cancer cells presents an 
opportunity for selectively targeted cancer therapies, including PDT.61,62 Such targeted 
therapies can either use lectins to target glycoconjugates on the surface of cancer cells, or use 
carbohydrates to target endogenous lectins.61 Even though the binding affinity between 
specific lectins and carbohydrates (kd values between 10-3-10-6 M) is not as high as 
antibody/antigen interactions, several studies showing effective glycotargeting have been 
reported.53,61,62 
The use of the lectin Jacalin to target the Thomsen-Friedenreich disaccharide (T antigen), 
overexpressed in over 90 % of primary human carcinomas, has been reported by Russell and 
co-workers.62 C11Pc-PEG-AuNPs were conjugated to Jacalin via EDC-NHS coupling to the 
terminal end of the PEG ligand (Figure 6a). Jacalin conjugated and unconjugated C11Pc-PEG-
AuNPs were compared for the treatment of HT-29 colon adenocarcinoma cells, which 
overexpress the T antigen. Jacalin has a high binding affinity towards the T antigen (kd = 500 
± 50 nM) so it was expected to selectively target HT-29 cells. Indeed, internalisation of the 
Jacalin conjugated C11Pc-PEG-AuNPs was enhanced (Figure 6b) as compared to non-
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conjugated C11Pc-PEG-AuNPs (Figure 6c). The enhanced internalisation induced high levels of 
cell death (ca. 95-98 %) post-PDT, a marked improvement from the non-conjugated C11Pc-
PEG-AuNPs (ca. 8 % cell death), which occurred following the necrotic pathway. Visualisation 
of cell death was confirmed by the dramatic change in cell morphology (Figure 6d), as well as 
the pink staining with the dead cell marker propidium iodide (Figure 6e).62  The comparison 
of Jacalin conjugated C11Pc-PEG-AuNPs with anti-HER2 antibody conjugated C11Pc-PEG-
AuNPs confirmed the optimal targeting ability of both ligands. While the significant difference 
between the kd value for the antibody and the lectin was thought to favour targeting by the 
antibody, the prevalence of the carbohydrate receptor on the cancer cell surface ensured that 
both targeting molecules induced comparable levels of phototoxicity in the HT-29 and SK-BR-
3 cells.54 
 
Figure 6. (A) Schematic representation of the Jacalin conjugated C11Pc-PEG-AuNPs used in this 
study. (B-E) Merged differential interference contrast and confocal fluorescence microscopy 
images of HT-29 colon adenocarcinoma cells incubated for 4 hours with (B) Jacalin-conjugated 
nanoparticles (2 μM C11Pc equivalent) and (C) non-conjugated nanoparticles (2 μM C11Pc 
equivalent). (D) After photodynamic therapy treatment, the cell morphology of HT-29 cells 
incubated with the Jacalin-conjugated nanoparticles dramatically changed, and (E) the HT-29 cells 
after photodynamic therapy with the Jacalin-conjugated nanoparticles stained positive for 
propidium iodide (5 mg/mL). Scale bars represent 10 mm. Figure reproduced from Obaid et al.62 
with permission from John Wiley and Sons © Wiley-VCH. 
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The Russell group has also reported the use of the carbohydrate lactose to target cancer 
cells.61 The authors successfully used a thiolated lactose, self-assembled on the surface of 
AuNPs, not only as a targeting ligand for PDT, but also as the stabilising agent of the AuNPs in 
aqueous solutions. The synthesis of AuNPs functionalised with a mixed monolayer of lactose 
and a C3Pc photosensitiser was reported. The use of the C3Pc photosensitiser was beneficial 
to induce high levels of singlet oxygen via MEF, as discussed above. The conjugated lactose-
C3Pc-AuNPs were tested in vitro using two different breast cancer cell lines, namely MDA-MB-
231 and SK-BR-3 cells. The MDA-MB-231 cells were shown to overexpress galectin-1, a 
galactose-binding lectin, on their surface and their selective binding to the lactose-C3Pc-
AuNPs was shown using an enzyme linked immunosorbent assay (ELISA). However, even 
though there was a selective interaction between lactose and the galectin-1 on MDA-MB-231 
cells and efficient intracellular uptake, there was not an enhanced photodynamic cell kill as 
compared to control untargeted AuNPs. The second cell line studied, SK-BR-3, did not show 
an overexpression of galectin-1. Nevertheless, PDT studies confirmed enhanced cell death 
when the SK-BR-3 cells were treated with lactose-C3Pc-AuNPs (97 % cell death) in comparison 
with unconjugated control AuNPs (75 % cell death) at a concentration as low as 0.05 μM 
following only a 3 h incubation. The selective targeting towards SK-BR-3 cells, that lack 
galectin-1, can be explained by the presence of other galactoside-binding receptors and 
suggested the investigation of glucose transporter 1. This study shows the remarkable 
potential of using carbohydrates for enhanced PDT in vitro and in vivo.61 
Peptides 
The use of peptides for PDT has been increasingly reported. As previously mentioned, the 
Burda and Broome groups engineered their Pc4-PEG-AuNPs to contain targeting peptides for 
brain tumours.63–66 These groups initially targeted the EGFR overexpressed on the surface of 
brain cancer cells using EGF peptides, which interact specifically with EGFR (kd = 22 nM).63 As 
previously described, the Pc4 photosensitiser was attached to the AuNPs via a weak N-Au 
bond stabilised by the presence of PEG. As a result, the Pc4 was entrapped in a ‘cage-like 
structure’ and its fluorescence was quenched. EGF peptides were then conjugated to the 
terminal chain of the PEG using EDC-NHS coupling. The effectiveness of these AuNPs relies on 
the effective release of Pc4 into the cancer cells. The presence of the EGF peptides was shown 
to enhance the intracellular uptake of Pc4 by a factor of ten. Higher uptake was possible due 
to a longer interaction between the AuNPs and the cell membrane, which allows more Pc4 to 
be released into the cells via receptor-mediated endocytosis. The endocytosed Pc4 moves 
towards the endosomes upon internalisation, in contrast with the Pc4 coming from non-
targeted AuNPs, which is directed towards the mitochondria.63,64 The use of EGF peptides to 
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target brain tumours was thus beneficial for the development of AuNPs able to cross the blood 
brain barrier and lead to efficient photodynamic cell kill and tumour reduction.63,64 The 
research was extended by using another peptide, transferrin, to target the transferrin 
receptor overexpressed in brain tumour malignancies.65 The authors conjugated a seven 
amino acid transferrin sequence to the Pc4-PEG-AuNPs, obtaining an average of 39 peptides 
per AuNP. In vitro studies showed a 2-3 fold improvement in the intracellular uptake of Pc4, 
which correlated with a good photodynamic efficacy in vivo. The main advantage of using 
transferrin was the ability to efficiently cross the blood-brain-barrier (BBB) and more 
importantly the possibility to use reduced drug concentrations, up to ten times less, to obtain 
the same PDT efficacy as that seen with untargeted AuNPs.65 Given the promising results seen 
with both EGF and transferrin peptides, the use of dual targeting was evaluated.66 The Pc4-
PEG-AuNPs were efficiently conjugated with both EGF and transferrin peptides, and tested in 
vitro and in vivo. Even though the dual targeting showed a remarkable improvement over 
untargeted AuNPs, the improvement was only moderate relative to the single-targeted AuNPs 
reported above.66 The use of the transferrin peptide was also reported by Yu et al..67 In their 
study, the authors prepared PSMA polymer coated AuNPs to which a layer of methylene blue 
was electrostatically attached, followed by EDC-NHS coupling to transferrin. The targeted 
AuNPs were reported to be internalised three times more efficiently by transferrin-
overexpressing HeLa cells as compared to untargeted AuNPs. The higher internalisation 
correlated with an increased cell death post-PDT, with levels of 30 % for free methylene blue, 
45 % for untargeted AuNPs and 65 % for transferrin-targeted AuNPs.67 Therefore, the use of 
either EGF or transferrin peptides has been shown to be highly efficient for the treatment of 
cancer.  
The receptor ephrin type B-receptor 4 (EphB4), a transmembrane protein overexpressed in 
several tumours, has been targeted using the TNYL (threonine-asparagine-tyrosine-leucine) 
peptide.68 Hollow gold nanospheres were functionalised with a thiolated PEI and a thiolated 
PEG pre-attached to TNYL peptides. The photosensitiser ICG was then incorporated within the 
system via a dehydration reaction with PEI. The synthesised nanosystem was used for 
combined PDT/PTT using NIR irradiation. The nanosystem was evaluated in vitro using a EphB4 
positive cell line, CT-26 mice colon cancer cells, and a EphB4 negative cell line, A549 human 
lung cancer cells. The internalisation by the cells was found to be higher for CT-26 cells via 
receptor-mediated endocytosis, which localise the targeted nanospheres into the lysosomes. 
Additionally, in vivo studies using Babl/c mice with CT-26 tumours showed that the TNYL 
targeted nanospheres were more efficient than untargeted nanospheres since, at the same 
concentration, they require a lower laser power to induce similar PDT effects. More 
importantly, the authors revealed that the mechanism by which tumours become resistant to 
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free ICG does not cause a problem for TNYL targeted nanospheres, which are still able to 
efficiently kill cancer cells.68  
Several studies have taken advantage of the acidic pH within tumour tissues for drug 
release.69–71 Wu et al. used RGD (arginine-glycine-aspartic acid) peptides to specifically target 
αvβ integrins overexpressed on the surface of cancer cells.69 The authors synthesised 14 nm 
AuNPs and functionalised them with 5ALA, which is converted to the photosensitiser PpIX, via 
an acid sensitive hydrazone bond, with RGD peptides and with a zwitteronic peptide sequence 
that provides ‘stealth-like’ properties to avoid protein adsorption. The RGD-5ALA-AuNPs were 
efficiently internalised by A549 cells, almost four times better than non-targeted 5ALA-AuNPs, 
confirming the targeting ability of the RGD. The hydrazone bond linking the AuNPs and the 
5ALA is broken at acidic conditions, such as the low pH found in tumour tissues. Therefore, 
5ALA is released into tumour cells upon internalisation. Even though PDT with RGD-5ALA-
AuNPs showed a remarkable improvement from the free 5ALA, the improvement relative to 
non-targeted 5ALA-AuNPs was only moderate.69 In another system, Liu et al. prepared gold 
nanorods (57.3 × 16.2 nm) covered with a 21 nm mesoporous silica shell, into which the 
photosensitiser ICG was embedded.70 The AuNRs were then functionalised with 3-
aminopropyltriethoxysilane (APTES), which could be linked through an amide bond to β-
cyclodextrin. The targeting agent in their system was an RLA (arginine-leucine-alanine) 
peptide, containing mitochondria targeting ability, which was attached to the cyclodextrin via 
host-guest interaction. Finally, a charge-reversible polymer made up of a chitosan 
oligosaccharide modified with PEG, linked to a 2,3-dimethylmaleic anhydride (DMA) using a 
weak acid sensitive amide bond, was attached to the AuNRs electrostatically to induce 
‘stealth-like’ properties. Similar to the previous study, the acidic environment in the tumour 
tissue leads to the dissociation of the DMA polymer, allowing the exposure of the RLA peptide, 
which drives the cellular uptake due to its strong mitochondria targeting ability. Upon 
internalisation, the conjugates can then be used for combined PDT/PTT using a NIR 
wavelength of 808 nm. This nanoconjugate was shown to have potential for combination 
therapies and allows for its functionalisation with other ligands, including chemotherapeutic 
drugs, to further enhance its tumour destruction ability.70 
Other important receptors involved in cancer progression, metastasis and angiogenesis are 
matrix metalloproteinases (MMP), especially MMP2.71  Xia et al. included MMP2 polypeptides 
in gold nanoclusters in order to target this receptor. Gold nanoclusters coated with 
glutathione (GSH) of 2 nm in size were functionalised with cis-aconitic anhydride modified 
doxorubicin, a chemotherapeutic drug, and chlorin e6 via EDC-NHS coupling and with 
PEGylated MMP2 polypeptides. The functionalised nanoclusters can be used for fluorescence 
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imaging combined with PDT and chemotherapy. Chemotherapy occurs when doxorubicin is 
released from the nanoclusters due to the acidic pH inside the tumours. Fluorescence imaging 
and PDT were both dependent on the chlorin e6 photosensitiser. The presence of the MMP2 
polypeptides allowed for an increased cell internalisation, together with an enhanced tumour 
destruction in vivo.71 
Aptamers  
Aptamers are made of single-stranded DNA or RNA oligonucleotides with high affinity towards 
specific target molecules.72 The selectivity towards their target makes them ideal for targeted 
drug delivery. Several studies using aptamers for targeted PDT have been reported in the 
literature.73–75 In the first study the aptamer AS1411, a 26-base guanine-rich oligonucleotide 
also known as anti-nucleolin aptamer, was conjugated to 13 nm AuNPs via Au-S bond.73 The 
G-quadruplex conformation adopted by the aptamer allows its interaction with nucleolin but 
it also makes it possible for porphyrins to be intercalated within the structure. Therefore, the 
photosensitiser N-methylmesoporphyrin IX (NMM) was conjugated to form NMM-AS1411-
AuNPs. The G-quadruplex structure has an enhancement effect of the fluorescence of NMM, 
which is further enhanced by interactions with the AuNPs. In vitro studies with HeLa cells, 
which overexpress nucleolin, confirmed the selective interaction between AS1411 and 
nucleolin, leading to an improved internalisation and thus efficient white light-mediated 
PDT.73 That same AS1411 aptamer was used as the targeting ligand for combined PDT/PTT 
and chemotherapy.74 Yi et al. synthesised DNA coated-AuNRs functionalised with doxorubicin 
and 5, 10, 15, 20-tetrakis(1-methylpyridinium-4-yl) porphyrin (TMPyP4) via the DNA assembly. 
Additionally, the AS1411 aptamer was hybridised with the DNA assembly, which had a 
complementary sequence. The use of AuNRs, together with TMPyP4 and doxorubicin opens 
the possibility for a combined PTT/PDT and chemotherapy treatment. NIR (808 nm) and white 
light can be used to trigger PTT and PDT, respectively. Additionally, irradiation of the AuNRs 
with 808 nm also induces the release of doxorubicin into the nucleus of the cells, leading to 
the chemotherapeutic effect. The use of combination therapies was reported to give the best 
results. More importantly, the presence of AS1411 led to a three-fold improvement in 
intracellular uptake by HeLa cells, which contributed to an enhanced cytotoxicity reaching ca. 
92 % cell death in contrast to the ca. 51 % cell death seen with non-targeted AuNRs.74 
Another aptamer, TLS11a has been reported to specifically recognise hepatocellular 
carcinoma cells.75 Zhang and co-workers created a targeting system based on the presence of 
an aptamer, but also taking advantage of the increased glutathione (GSH) activity inside 
tumour cells. GSH activity involves cleaving disulfide bonds. The authors functionalised AuNPs 
with a thiolated TLS11a aptamer, which was labelled with chlorin e6 and coordinated to a 
27 
 
Cu(II) complex, which allowed the functionalisation with the anti-tumour prodrug AQ4N (di-
N-oxide of 1,4-bis[2-dimethyllaminoethyl-amino]5,8-dihydro xyanthracene-9,10-dione, also 
known as banoxantrone). Reduction of AQ4N in hypoxic conditions produces the toxic drug 
AQ4, with anti-tumour activity. The fluorescence of chlorin e6 was quenched in the presence 
of the AuNPs. However, upon internalisation by cancer cells, the fluorescence can be regained 
due to the cleaving of the thiol bond between the AuNPs and the TLS11a aptamer by the 
enhanced tumour GSH activity. As a result, the chlorin e6-TSL11a-Cu(II)-AQ4N complex is 
released. Furthermore, the acidic pH in the tumour tissues leads to the release of both Cu(II) 
and AQ4N. At this point, several processes can take place. The release of Cu(II) ions induces 
the aggregation of the AuNPs, which is advantageous for the treatment of the cancer cells via 
PTT. Furthermore, the release of chlorin e6 is key for the treatment of the cells via PDT. Upon 
670 nm irradiation for PDT, the tumour tissue becomes hypoxic, which is a suitable 
environment for the reduction of AQ4N into the toxic drug AQ4. Therefore, following 
enhanced cell internalisation due to the TSL11a aptamer, a combination of PTT/PDT and 
chemotherapy takes place, making these AuNPs ideal for multimodal cancer treatment.75 The 
research by Zhang et al. builds on a previous study in which the authors targeted the increased 
GSH activity in cancer cells without the presence of other external targeting ligands.76 In their 
work, 40 nm AuNPs functionalised with a thiolated heparin conjugated to the photosensitiser 
pheophorbide A (PhA) were synthesised. Heparin was deliberately chosen due to its water 
solubility, biocompatibility and anti-tumour activity. Upon internalisation by cancer cells, the 
GSH activity cleaves the PhA-heparin from the AuNPs, allowing the PhA to regain its 
fluorescence properties and induce effective PDT cytotoxicity in A549 tumours both in vitro 
and in vivo.76 
Folic and hyaluronic acids 
The folate receptor has become an important target for cancer therapies given its 
overexpression in tumours, including ovarian, breast and lung cancers amongst others, and 
its low expression in healthy tissue.77 The use of folic acid has been widely reported for the 
specific targeting of folate, including studies with gold nanoparticle-mediated PDT.78–80 Gold 
quantum clusters, gold nanoclusters and gold nanorods are some of the gold structures used 
for folate-targeted PDT. Nair et al. synthesised gold quantum clusters covered with lipoic acid, 
to which folic acid and the photosensitiser PpIX were conjugated using EDC-NHS coupling.78 
The clusters accumulated in C6 glial tumours, which overexpress the folate receptor, in vivo 
only 3 h after injection. The enhanced accumulation due to the folate targeting was optimal 
for the combination of fluorescence imaging and PDT within the same system.78 In a similar 
study, Zhang et al. conjugated a PEGylated folic acid to GSH-coated gold nanoclusters, 
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followed by entrapping chlorin e6 via hydrophobic interactions with the PEG and passive 
adsorption to the gold surface.79 In vitro evaluation was performed in folate positive MGC-
803 gastric cancer as well as folate negative GES-1 gastric epithelial cells. The results showed 
increased internalisation in the cancer cells as compared to the epithelial cells, thus 
confirming the specific interaction between folic acid and the folate receptor, which lead to 
enhanced PDT. In vivo studies further confirmed the potential of the folic acid conjugated gold 
nanoclusters since they were easily accumulated within the tumour tissue, only 10 minutes 
after injection, leading to effective inhibition of tumour growth.79 Finally, in a separate study, 
CTAB coated AuNRs functionalised with a folic acid-containing block copolymer and thiolated 
chlorin e6, in the form of NH2-SS-chlorin e6, were used for targeted PDT of breast cancer 
cells.80 The use of a thiolated chlorin e6 allows its release from the AuNRs upon internalisation 
by the cancer cells, due to the enhanced GSH activity found in tumours. Upon release, chlorin 
e6 can be used for PDT, in combination with PTT therapy via the AuNRs. Internalisation of the 
folic acid targeted AuNRs was better for MCF-7 breast cancer cells than for A549 lung cancer 
cells, given that overexpression of the folate receptor is only seen in MCF-7 cells. The 
enhanced internalisation correlated with an improved therapeutic effect for both therapies, 
PDT at 670 nm and PTT and 880 nm. The combination of PDT with PTT, even though was found 
to be beneficial relative to single PTT therapy, only showed a moderate improvement from 
the treatment of the cells with PDT only, which was already efficient by itself.80 The three 
studies here described confirm the selectivity of folic acid towards folate receptors and the 
potential of using this targeting ligand for enhanced cell kill in cancer therapy. 
The glycoproteins CD44 are highly expressed in many tumours and are involved in metastasis 
and tumour progression.81 CD44 glycoproteins specifically bind hyaluronic acid thus making 
them an attractive receptor for targeted PDT. Tham et al. used hyaluronic acid for an 
enhanced PDT of HeLa cells, which overexpress CD44 on their surface. The authors prepared 
AuNRs encapsulated with a silica layer, to which a silica modified zinc phthalocyanine (ZnPc-
Si) was attached. Hyaluronic acid was then conjugated electrostatically, creating a layer 
around the AuNRs. Confirmation of the targeting ability of hyaluronic acid was obtained by in 
vitro studies with CD44 positive HeLa cells and CD44 negative MCF-7 cells. Following a 24 h 
incubation period, a three-fold higher uptake of AuNRs was observed for HeLa cells, as 
confirmed by confocal microscopy, flow cytometry and inductively coupled plasma optical 
emission spectrometry (ICP-OES). Upon internalisation, irradiation of the cells with a 730 nm 
laser activated both PDT, via the ZnPc, and PTT, via the AuNRs. The combination treatment 
further confirmed the selective interaction between hyaluronic acid and CD44 since, while 
only 48 % of MCF-7 cells died, up to 79 % of HeLa cells were destroyed.81 This study shows the 
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advantages of using hyaluronic acid for the selective targeting of CD44-overexpressing 
tumorigenic cells. 
Conclusions 
The present paper has provided a state-of-the-art review of the most recent advances in gold 
nanoparticle-mediated photodynamic therapy of cancer. It is clear the combination of 
photosensitisers with gold nanoparticles is advantageous for PDT. Gold nanoparticles are 
biocompatible and have a low intrinsic toxicity, which makes them ideal candidates for 
biological applications. Additionally, their large surface area-to-volume ratio allows their 
functionalisation not only with photosensitisers but also with many other ligands. The use of 
certain polymers such as PEG can avoid protein adsorption and opsonisation via the RES, thus 
increasing the blood circulation, beneficial for the increased uptake of nanoparticles in the 
tumour tissue. More importantly, the combination of gold nanoparticles with targeting 
ligands, i.e., actively targeted PDT, can further enhance the partial selectivity of the 
photosensitisers to a specific tumour. 
Another important advantage for the use of gold nanoparticles and other gold nanostructures 
is the possibility to combine PDT with other anti-cancer therapies. Many gold structures, 
particularly gold nanorods, are ideal for PTT, based on the localised increase in temperature 
inside the tumour, which leads to its destruction. The additional functionalisation of AuNPs 
with a chemotherapeutic drug, such as doxorubicin, opens the possibility to treat cancers via 
chemotherapy. Many studies have reported that the combination of two or more of such 
therapies greatly increases the inhibition of tumour growth and destruction of cancer cells. 
The use of photosensitiser functionalised AuNPs is not restricted to therapeutics. 
Theranostics, by which diagnosis and therapy is performed using the same nanosystem, can 
be achieved by combining fluorescence imaging of the tumours with PDT and several 
examples have been described.  
The investigation of AuNPs for PDT has seen a considerable increase since the first report in 
2002. The versatility of AuNPs for functionalisation with both photosensitiser and targeting 
molecules coupled with combined therapeutic modalities ensures that gold nanoconjugates 
have an important future for enhanced cancer therapy. 
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